ZFGN - Zafgen, Inc.

NasdaqGS - NasdaqGS Real Time Price. Currency in USD
10.35
+0.10 (+0.98%)
As of 1:27PM EDT. Market open.
Stock chart is not supported by your current browser
Previous Close10.25
Open10.25
Bid10.30 x 1000
Ask10.33 x 900
Day's Range10.20 - 10.46
52 Week Range3.37 - 12.35
Volume37,920
Avg. Volume273,913
Market Cap380.938M
Beta (3Y Monthly)-1.40
PE Ratio (TTM)N/A
EPS (TTM)-2.09
Earnings DateNov 5, 2018 - Nov 9, 2018
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target Est13.00
Trade prices are not sourced from all markets
  • GlobeNewswire15 days ago

    Zafgen to Present Data from Multiple Nonclinical, IND-Enabling Studies of ZGN-1258 at the 2018 Foundation for Prader-Willi Research Family Conference

    Zafgen, Inc. (ZFGN), a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range of metabolic diseases, announced today results from three nonclinical, Investigational New Drug (IND)-enabling studies of ZGN-1258 to be presented at the 2018 Foundation for Prader-Willi Research (FPWR) Family Conference taking place in Las Vegas October 4 – 6, 2018. ZGN-1258 is Zafgen’s second-generation, novel investigational MetAP2 inhibitor for the treatment of rare metabolic disorders, including Prader-Willi syndrome (PWS), designed to decrease hyperphagia, change the way the body metabolizes fat, and reduce fat mass.

  • Simply Wall St.21 days ago

    Who Owns Zafgen Inc (NASDAQ:ZFGN)?

    Every investor in Zafgen Inc (NASDAQ:ZFGN) should be aware of the most powerful shareholder groups. Institutions often own shares in more established companies, while it’s not unusual to see insiders Read More...

  • Amarin and Square are among the most important stock charts to watch
    MarketWatch23 days ago

    Amarin and Square are among the most important stock charts to watch

    Amarin and Square have rallied on separate news stories, and both top our charts to watch today, along with two others looking strong technically. Amarin (AMRN) followed through Tuesday, up 60 cents to $13 on huge volume of 106 million shares traded, after surging 300% Monday on news of positive clinical developments.

  • GlobeNewswire2 months ago

    Zafgen to Present at the Wedbush PacGrow Healthcare Conference

    BOSTON, Aug. 08, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • Associated Press2 months ago

    Zafgen: 2Q Earnings Snapshot

    On a per-share basis, the Boston-based company said it had a loss of 57 cents. The results topped Wall Street expectations. The average estimate of three analysts surveyed by Zacks Investment Research ...

  • GlobeNewswire2 months ago

    Zafgen Reports Second Quarter 2018 Operating and Financial Results

    Phase 1 clinical trial for ZGN-1258 for Prader-Willi syndrome expected to begin in the fourth quarter 2018. Multiple ZGN-1258 nonclinical studies accepted for presentation at upcoming Foundation for Prader-Willi ...

  • ACCESSWIRE2 months ago

    Zafgen, Inc. to Host Earnings Call

    NEW YORK, NY / ACCESSWIRE / August 7, 2018 / Zafgen, Inc. (NASDAQ: ZFGN ) will be discussing their earnings results in their Q2 Earnings Call to be held on August 7, 2018 at 4:30 PM Eastern Time. To listen ...

  • Benzinga3 months ago

    The Daily Biotech Pulse: Zafgen Executive Departs; Adamas, Acceleron Accelerate On Earnings

    Here's a roundup of top developments in the biotech space over the last 24 hours. Scaling the Peaks (Stocks hitting 52-week highs on Aug. 2) Akcea Therapeutics Inc (NASDAQ: AKCA ) Arbutus Biopharma Corp ...

  • GlobeNewswire3 months ago

    Zafgen Announces Departure of President and Chief Scientific Officer Dr. Thomas Hughes

    Zafgen, Inc., (ZFGN), a clinical-stage biopharmaceutical company using its proprietary knowledge of MetAP2 systems biology to help patients affected by a range of metabolic diseases, announced today that Thomas Hughes, Ph.D., has resigned from his role as President and Chief Scientific Officer at Zafgen to accept a Chief Executive Officer role at a privately held biotechnology company. Dr. Hughes is also stepping down from Zafgen’s Board of Directors. Dr. Hughes’s last day with Zafgen will be in the coming weeks and a search for a successor is underway.

  • GlobeNewswire3 months ago

    Zafgen to Present at the Canaccord Genuity 38th Annual Growth Conference

    BOSTON, Aug. 01, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • GlobeNewswire3 months ago

    Zafgen to Host Conference Call to Discuss Second Quarter 2018 Financial Results

    BOSTON, July 31, 2018-- Zafgen, Inc., a clinical-stage biopharmaceutical company leveraging its proprietary knowledge of MetAP2 systems biology to develop novel therapies for patients affected by a range ...

  • Zafgen (ZFGN) Surges: Stock Moves 9.2% Higher
    Zacks3 months ago

    Zafgen (ZFGN) Surges: Stock Moves 9.2% Higher

    Zafgen (ZFGN) shares rose more than 9% in the last trading session, amid huge volumes.

  • 3 Biotech Stocks That Soared This Week: Are They Buys?
    Motley Fool4 months ago

    3 Biotech Stocks That Soared This Week: Are They Buys?

    Can these high-flying biotech stocks keep up their momentum?

  • Here's Why Zafgen Inc. Rose by Double Digits Today
    Motley Fool4 months ago

    Here's Why Zafgen Inc. Rose by Double Digits Today

    The early-stage biopharma announced the pricing of a common stock offering.

  • ACCESSWIRE4 months ago

    Today's Research Reports on Trending Tickers: Exelixis and Zafgen

    NEW YORK, NY / ACESSWIRE / June 26, 2018 / U.S. equities plunged on Monday, as indexes posted their biggest one-day decline in week, as fresh threats from President Trump added to the uncertainties of ...

  • Benzinga4 months ago

    The Week Ahead In Biotech: Conferences, Clinical Trials And IPOs

    Sentiment toward biotech stocks turned neutral this week amid a lack of any major sectorwide catalysts. That said, there were wild swings in select stocks in reaction to clinical trial announcements.  ...